Caribou Biosciences, Inc.
Caribou Biosciences develops CRISPR genome-edited CAR-T cell therapies for hematologic malignancies.
6-KSep 21Latest SEC filing, period to Jun 30
Aug 13Latest story
August 2026
Sign inSign inCaribou Biosciences develops CRISPR genome-edited CAR-T cell therapies for hematologic malignancies.